IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.

IPI-9119 (IPI9119) is a potent, selective, and irreversible inhibitor of fatty acid synthase (FASN) with IC50 of 0.3 nM in biochemical assays.

Ipidacrine hydrochloride hydrate is a reversible acetylcholinesterase (AChE) inhibitor that directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels.

Ipidacrine hydrochloride is a reversible acetylcholinesterase (AChE) inhibitor that directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels.

Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

Ipratropium bromide

IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pKi of 7.85.

IQ-1 has many functions such as decreasing Wnt-stimulated phosphorylation, maintaining the pluripotency of murine ESCs, preventing PP2A/Nkd interaction and so on.

IQ-1S is a selective JNK3 inhibitor (IC50 values are 390, 360 and 87 nM for JNK1, 2 and 3 respectively).

IQM-266 (IQM266) is a DREAM (Downstream Regulatory Element Antagonist Modulator) ligand (Kd=4.63 uM), inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner.

IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression, reverses the inhibitory effect of HBx protein on activity of the Dicer endoribonuclease.

IRAK inhibitor 1 is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.

IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .

IRAK inhibitor 6 is interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor .

IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

Irampanel (BIIR 561) is a combined antagonist of AMPA receptors (AMPAR) and voltage-dependent sodium channels.

Irampanel (BIIR 561) is a combined antagonist of AMPA receptors (AMPAR) and voltage-dependent sodium channels.

Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

Irdabisant (CEP-26401) is a potent, selective, orally active histamine H3 receptor antagonist with Ki of 2 nM and 7 nM for human and rat H3Rs, respectivity.

Irdabisant (CEP-26401) is a potent, selective, orally active histamine H3 receptor antagonist with Ki of 2 nM and 7 nM for human and rat H3Rs, respectivity.

IRE1α-IN-3 is a novel, potent IRE1α RNase inhibitor with EC50 of 0.82 uM.

Irigenin, an α-glucosidase inhibitor, which has anti-inflammatory, anti-cancer, and anti-metastatic effects. Irigenin can inhibit the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 proteins and mRNAs without an appreciable

Irinotecan hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.

Irinotecan(CPT-11) prevents DNA from unwinding by inhibition of topoisomerase 1.

Irosustat（STX64） is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity.

Irsogladine maleate is a selective PDE4 inhibitor that facilitates gap junction intercellular communication through muscarinic acetylcholine receptor binding. It is a potent inhibitor of angiogenesis in wild-type and plasminogen activator-deficient mice.

IS-741 (Fuzapladib, IS741) is a synthetic anti-inflammatory agent that shows inhibitory effect on cytosolic phospholipase A2 (cPLA2)..

ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects .

ISA27 is a novel small molecule that blocks p53-MDM2 interaction and induces apoptosis both in vitro and in vivo.

Isatin is an endogenous MAO inhibitor.

Isatoribine is a selective agonist of TLR7

Isavuconazole(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata.

Isavuconazonium is a water-soluble prodrug form of the azole antifungal isavuconazole (ISA).

ISCK03 is a cell-permeable inhibitor of SCF-mediated c-kit activation, completely blocking phosphorylation of c-kit in human melanoma cells at a concentration between 1 and 5 µM.

Isepamicin

Isepamicin Sulphate is an aminoglycoside antibiotic, which inhibits bacterial protein synthesis by targeting the bacterial 30S ribosomal subunit.

ISO-66 is a novel, highly stable, small-molecule MIF inhibitor that inhibits MIF tautomerase activity with IC50 of 1.4 uM.

ISO-92 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity with IC50 of 0.55 uM..

Isoastragaloside IV is a triterpene oligoglycoside isolated from Astragali Radix.

Isobavachalcone is a natural chalcone first isolated from P. corylifolia that displays antibacterial, antifungal, anticancer, anti-reverse transcriptase, antitubercular, and antioxidant activities in various research models.

Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), produces ROS, and induces cytotoxicity in cancer cells in an NQO1-dependent manner.

Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro.

Isocryptotanshinone is a potent signal transducer and activator of transcription 3 (STAT3) and protein tyrosine phosphatase 1B PTP1B inhibitor, with an IC50 of 56.1 μM for PTP1B.

Isoginkgetin (Iso-ginkgetin.

Isoliquiritigenin

Isoliquiritin has significant antidepressant-like, antifungal and anti-cancer activities. It induces apoptotic cell death through upregulating p53 and p21 in the A549 non-small cell lung cancer cells and inhibit the p53-dependent pathway and showed crosst

Isomaltose is a glucose disaccharide with an α-(1→6) linkage, as opposed to the α-(1→4) linkage found in maltose.

Isomangiferin is the major tetracyclic oxindole alkaloid components of Uncaira species, inhibits NMDA receptor with IC50 of 43.2 uM, also blocks calcium channel.

Isomigrastatin (iso-Migrastatin) is an analogue of migrastatin that shows potent antiproliferative effect on tumor cell lines and selectively inhibits translation.

Isoniazid is an antibacterial agent used primarily as a tuberculostatic.Target: AntibacterialIsoniazid is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme that in M. tuberculosis is called KatG [1]. KatG couples the isonicotinic acyl with NADH to form isonicotinic acyl-NADH complex. This complex binds tightly to the enoyl-acyl carrier protein reductase known as InhA, thereby blocking the natural enoyl-AcpM substrate and the action of fatty acid synthase. This process inhibits the synthesis of mycolic acid, required for the mycobacterial cell wall. A range of radicals are produced by KatG activation of isoniazid, including nitric oxide, which has also been shown to be important in the action of another antimycobacterial prodrug PA-824 [2, 3]. Isoniazid is bactericidal to rapidly dividing mycobacteria, but is bacteriostatic if the mycobacteria are slow-growing [4].

Isonicotinic acid is a metabolite of isoniazid. It is an isomer of nicotinic acid.

Isoprenaline Hydrochloride is a non-selective beta-adrenergic agonist and structurally similar to adrenaline.

Isoquercitrin is an effective antioxidant and an eosinophilic inflammation suppressor.

Isoquercitrin is an inhibitor of Wnt/β-catenin that acts downstream of the β-catenin nuclear translocation; it is also a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders.

Isoscopoletin possesses inhibitory activity against hepatitis B virus (HBV) replication; it also shows substantial inhibition against multi-drug resistant CEM/ADR5000 cells and human CCRF-CEM leukaemia cells, with the IC50 value is 1.6 and 4.0 microM, res

Isosilybin is a flavanolignan found in the extract of S. marianum fruits with antioxidant and anticancer activities.It inhibits lipid peroxidation in rat liver microsomes (IC50 = 32 μM) and reduces ADP/Fe3+-induced malondialdehyde (MDA) production and lac

Isosorbide mononitrate(Isosorbide-5-mononitrate) is a nitrate-class compound used for angina pectoris; acts by dilating the blood vessels so as to reduce the blood pressure.

Isosteviol is a derivative of stevioside, a constituent of Stevia rebaudiana, which is commonly used as a noncaloric sugar substitute in Japan and Brazil.

Isotanshinone I has inhibitory activity against α-glucosidase and formation of AGE, with IC50s of 1.13, 0.432 μM for α-glucosidase and AGE, respectively.

Isotanshinone IIA, an abietane-type diterpene metabolite, could non-competitively inhibit Protein Tyrosine Phosphatase 1B (PTP1B) activity with an IC50 0f 11.4 μM.

Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM.

Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne. It was first developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.

Isovitexin, a food phytochemical contained in dietary rice products, it exhibits in vivo α-glucosidase inhibition, it possesses antihyperglycemic, neuroprotective, anti-inflammatory and anti-oxidant activities. Isovitexin inhibited xanthine oxidase with a

Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively.

Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM.

ISRIB (trans-isomer), the trans-isomer of ISRIB, is a potent and selective PERK inhibitor with IC50 of 5 nM.

iST2-1 is a first-in-class, in vivo active ST2 (suppression of tumorigenicity 2) inhibitor with IC50 of 56.14 and 54.62 uM in AlphaLISA and the HEK-Blue IL-33 assay, respectively.

iST2-2 is a novel ST2 (suppression of tumorigenicity 2) inhibitor active in vivo.

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

Istradefylline(KW6002) is a very potent, selective and orally active adenosine A2A receptor antagonist(Ki=2.2 nM) in experimental models of Parkinson's disease.

ISX-9 is a small molecule inducer of adult neural stem cell differentiation both in vitro and in vivo.

It is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.

IT 901 is a c-Rel inhibitor (IC50 = 3 μM). Inhibits IL-2 expression in activated T-cells in vitro.

IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.

ITD-1 is a novel and highly selective TGFβ pathway inhibitor. ITD-1 molecule turns stem cells into heart cells.

ITI-214 is a potent, selective phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

Itraconazole (Sporanox)

ITSA-1 (ITSA1) is an HDAC activator via TSA suppression, but shows no activity towards other HDAC inhibitors.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITZ-1 is a client-selective Hsp90 inhibitor that efficiently induces heat shock factor 1 (HSF1) activation, selectively inhibits IL-1β-induced MMP-13 production (IC50=0.51 uM) via inhibition of ERK activation.

IU1 is a selective USP14 inhibitor. IU1 prevents ventilator-induced lung injury in rats.

IU1-47 is a potent, selective small-molecule inhibitor of USP14 with IC50 of 0.6 uM, shows 10-fold more potent over IU1 and retains specificity for USP14; accelerates the rate of degradation of wild-type tau, the pathological tau mutants P301L and P301S, and the A152T tau variant in primary neuronal cultures, a specific residue in tau, lysine 174, is critical for the IU1-47-mediated tau degradation by the proteasome; stimulates autophagic flux in primary neurons.

Ivabradine, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent.

Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

IWP L6 is a Porcn inhibitor with EC50 of 0.5 nM.

IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses.

IWP-3 is a selective small molecule wnt inhibitor, prevents palmitylation of Wnt proteins by Porcupine (Porcn), a membrane-bound O-acyltransferase, thereby blocking Wnt secretion and activity1.

IWP-O1 is a porcn inhibitor with an EC50 value of 80 pM in a cultured cell reporter assay of Wnt signaling and effectively suppresses the phosphorylation of Dvl2/3 in HeLa cells.

IWR-1 (endo-IWR 1) is a Wnt pathway inhibitor with IC50 of 180 nM, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.

Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors.

J-113397 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor/ORL1) antagonist with IC50 of 2.3 nM.

J-147 is a potent neuroprotective and neurotrophic compound.

J8-C8 is a small-molecule inhibitor of bacterial N-acyl-homoserine lactone synthase (acyl-HSLs) TofI with IC50 of 35 uM for toxoflavin production.

JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM).

JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2.

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectiv

JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM.

JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.

Janex 1 selectively inhibits the tyrosine kinase activity of JAK3 with an IC50 value of 78 µM without affecting the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM).

Jarin-1 is the first small-molecule inhibitor of JAR1 (IC50=3.8 uM) that inhibits jasmonate responses in Arabidopsis thaliana.

JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.

JBJ-01-162-04 is a small molecule targeting the flavivirus E protein with broad-spectrum activity, shows activity against DENV in the infectivity assay with IC90 of 0.1 uM.

JBJ-16-111 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E..

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JCP251 is a selective small molecule inhibitor of S. aureus serine hydrolase FphB, effectively reduces infectivity in vivo..

JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.

JD5037 is an inverse agonist of peripheral cannabinoid 1 (CB1) receptors (Ki = 0.35 nM).

JDTic 2Hcl is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

Jervine(11-Ketocyclopamine) is a naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog(Shh) signaling; Jervine is an inhibitor of Smo.

JF5 (PAR1 inhibitor JF5) is an allosteric inhibitor of PAR1 that binds to helix 8 of the receptor.

JG-231 is an allosteric inhibitor that disrupts the Hsp70-BAG3 interaction (Ki=0.11 uM), inhibits breast cancer cells MCF-7 and MDA-MB-231 with IC50 of 0.12 and 0.25 uM, respectively.

JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor.

JH-IX-179 is a novel highly potent and selective type I ATP competitive pan-FLT3 inhibitor with IC50 of 4 and 10 nM for FLT3-ITD and D835Y, respectively.

JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM (sirtuin deacylation activity), increase intracellular K-Ras4a lysine fatty acylation.

JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM, also shows high potency against a variety of other frequently observed mutants (G1269A, S1206Y, F1174L and C1156Y).

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

JH-XI-10-02 is a CDK8 PROTAC based on the CDK8 inhibitor JH-VIII-49, induces partial degradation of CDK8 in Jurkat cells with IC50 of 159 nM..

JI051(JI-051) is a specific compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).

JI130 (JI-130) is a specific Hse1 inhibitor that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

JK-184 is a potent downstream hedgehog (Hh) signaling inhibitor that prevents Gli-dependent transcriptional activity (IC50 = 30 nM).

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases.

JK-P3 is a VEGFR-2 inhibitor.

JM6 (KMO inhibitor JM6) is an orally bioavailable small-molecule prodrug of Ro 61-8048, which is an inhibitor of kynurenine 3-monooxygenase (KMO).

JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM).

JMV 2959 (AEZS-123) is a potent ghrelin receptor (GHS-R1A) antaognist with binding IC50 of 32 nM.

JNc-440 is a small molecule that significantly and specifically strengthens the TRPV4-KCa2.3 interaction in mouse endothelial cells, but does not systemically activate TRPV4 and KCa2.3.

JND3229 is a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy (IC50 = 5.8 nM).

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 39220675 is potent and selective, brain penetrant H3 antagonist with Ki of 1.4 nM, pA2 of 9.42 for hH3.

JNJ 42153605 is a positive allosteric modulator of the metabotropic glutamate 2 receptor.

JNJ0966 is a highly selective compound that inhibited activation of MMP-9 zymogen and subsequent generation of catalytically active enzyme.

JNJ-10198409 is a highly potent, selective PDGFRβ inhibitor with IC50 of 4.2 nM.

JNJ-10229570 (JNJ10229570) is a novel potent, selective melanocortin receptor MC1R and MC5R antagonist with binding IC50 of 270 nM and 200 nM, respectively.

JNJ16567083 (EMQMCM) is a potent and selective mGluR1 antagonist that shows neuroprotective effects in some hypoxia-ischemia models.

JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-1A is a novel Dengue virus (DENV) NS4B inhibitor that inhibits DENV-2 sub-genomic replicon at 0.7 μM, in the absence of cytotoxicity.

JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures.

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

JNJ-26993135 is a potent, selective leukotriene A4 hydrolase (LTA4H) inhibitor, inhibits both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H with IC50 of 10 nM.

JNJ-28307474 is a potent, selective antagonist of the histamine H4 receptor (H4R), inhibits LPS-induced TNF production..

JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.

JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R)..

JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents).

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors.

JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM.

JNJ-38158471(KDR) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50=40nM. It also inhibits closely related tyrosine kinases, Ret (180nM) and Kit (500nM). It has no significant activity (>1 microM) against VEGFR-1 and VEGF

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively.

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM.

JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively.

JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor..

JNJ-39933673 is a potent, selective SGLT2 inhibitor..

JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation..

JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively.

JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.

JNJ-42165279 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70nM.

JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A.

JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively.

JNJ4796 (JNJ 4796, JNJ-4796) is an orally active small-molecule fusion inhibitor of influenza virus hemagglutinin (HA) with EC50 of 33 nM (H1N1 neutralization).

JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively.

JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.

JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM..

JNJ-5207852 is a selective and potent histamine H3 receptor (H3R) antagonist, with pKis of 8.9, 9.24 for rat and human H3R, respectively.

JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety..

JNJ525 is a small molecule inhibitor of TNFα that prevents the formation of TNFα complexes with TNFR1 and TNFR2 with IC50 of 1.2 uM and 1.1 uM in the TR-FRET assay, respectively..

JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV.

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.

JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4.

JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2.

JNJ-632 is a novel and potent inhibitor of HBV replication in vitro across genotypes A-D.

JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.

JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.

JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.

JPC-3210 is a potent antimalarial agent with IC50 of 2.5-19 nM, remains activity against multidrug-resistant Plasmodium falciparum lines with little cytotoxicity in mammalian cell lines.

JPH203 (KYT-0353) is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition), but not LAT2.

JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.

JQ1-VHL-PROTAC is a novel PROTAC synthesis..

JQ-35, (S)- is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.

JQEZ5 is a novel and potent EZH2 inhibitor.

JSF-4088 (JSF4088) is a novel antitubercular agent with potent in vitro antitubercular potency (MIC=19 nM), with no significant Vero cell cytotoxicity (CC50 >120 uM)..

JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).

JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.

JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.

JTE-852 is a novel potent, selective, ATP-competitive Syk kinase inhibitor with IC50 of 1.25/1.28 nM for human/rat Syk, respectively.